MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$4,675,571
EPS
-$0.11
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
2,138,204
2,763,340
1,800,057.5*
2,849,510
General and administrative
2,543,448
2,590,205
2,097,690*
1,936,267
Total operating expenses
4,681,652
5,353,545
3,897,747.5
4,785,777
Loss from operations
-4,681,652
-5,353,545
-3,897,747.5*
-4,785,777
Interest income, net
61,062
93,052
63,431*
78,074
Foreign exchange loss (gain), net
49,089
-165,173
138,786*
-27,382
Loss before income tax
-4,571,501
-5,425,666
-3,695,530.5*
-4,735,085
Income tax
104,070
183,066
-174,621.5*
549,288
Net loss
-4,675,571
-5,608,732
-3,520,909
-5,284,373
Basic EPS
-0.11
-0.13
-0.105
-0.15
Diluted EPS
-0.11
-0.13
-0.105
-0.15
Basic Average Shares
42,879,541
42,230,248
33,565,425
34,998,060
Diluted Average Shares
42,879,541
42,230,248
33,565,425
34,998,060
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$4,675,571
(19.51%↑ Y/Y)
Loss before income
tax
-$4,571,501
(19.34%↑ Y/Y)
Income tax
$104,070
(-26.30%↓ Y/Y)
Interest income, net
$61,062
(43.45%↑ Y/Y)
Foreign exchange loss
(gain), net
$49,089
(107.91%↑ Y/Y)
Loss from operations
-$4,681,652
(8.01%↑ Y/Y)
Total operating
expenses
$4,681,652
(-8.01%↓ Y/Y)
General and
administrative
$2,543,448
(9.13%↑ Y/Y)
Research and development
$2,138,204
(-22.50%↓ Y/Y)
Buy us a coffee
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)